According to the National Cancer Institute, cancer has a major impact on the population of U.S. and across the world. The NCI reports approximately 1,685,210 new cases of cancer were diagnosed in 2016. Also, reports demand for efficient detection tests that can be sufficed with the help of ELISA test kits. Moreover, increasing demand for cost-effective diagnostic tool is one of the factor aiding the growth of ELISA market, especially in the low and middle income economies.
For instance, in October 2017, the Nigerian government and World Health Organization (WHO) launched a campaign to vaccinate around 874,000 people against yellow fever in two states of the country Kwara and Kogi in alliance with the International Coordination Group. The samples of the patients suspected with yellow fever were further tested with the help of ELISA test at the Pasteur Institute in Dakar. However, availability of alternate immunoassays and cross reactivity projected by these tests can hinder the market growth. Development of cost-effective ELISA tests with improved reliability and accuracy can provide potential opportunity for market players to strategize their growth in the global ELISA market.
Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1505
Extensive research and development in the field of immunoassay and diagnostics is leading to increasing applications and novel approaches for incorporation of ELISA in various medical fields. This has resulted in expansion of the range of Enzyme Linked Immunosorbent Assay (ELISA) products used in clinical and medical approaches.
For instance, Inova Diagnostics, in November 2016, received U.S. FDA approval for QUANTA Lite, a Calprotectin Extended range of quantitative ELISA assay that aids in the diagnosis of Inflammatory Bowel Disease (IBD) and helps to differentiate IBD from Irritable Bowel Syndrome (IBS). Moreover, a recent test is developed by Center for Infection and Immunity at University of Columbia in March 2018, extends a window for accurate detection of Zika infection, which is complex with molecular diagnostics procedures.
The new ZIKV-NS2B-concat ELISA is a faster, less expensive blood test, and clinical tool for accurate detection of Zika from weeks to months after onset of infection facilitating a powerful tool for the clinicians to make quick decisions for their patients. In July 2015, Bio-Rad Laboratories, Inc. received the U.S. Food and Drug Administration pre-market approval for BioPlex 2200 HIV Ag-Ab assay, which is the company's fifth generation HIV diagnostic test that produced efficient diagnostic test results for HIV.
For instance, in March 2017, Thermo Fisher Scientific, Inc. acquired Core Informatics and added it to analytical Instruments segment to strengthen its existing informatics solutions and bio production offerings. Furthermore, the company players are also focusing on research and development for introducing novel ELISA assays and test kits in to the market to stand out and retain their positions in the market.
Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1505
The key players operating in global Enzyme Linked Immunosorbent Assay (ELISA) Market include Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd.
About Us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com